Disruptive Technology ChannelCancer Detection Meets Portfolio Perfection: The ARKG ETFBy Tom LydonApril 13, 2021
Disruptive Technology ChannelHow ARKG’s Genomics Will Personalize Cancer TreatmentBy Tom LydonMarch 31, 2021
Disruptive Technology ChannelSynthetic Biology: What It Is and Why ‘ARKG’ Is So Levered to ItBy Tom LydonMarch 16, 2021
FeaturedETFGI Reaches New ETF Record of $5.52 Trillion In Invested AssetsBy Aaron NeuwirthFebruary 16, 2021
Disruptive Technology ChannelLiquid Biopsies? Just Another Day in the Life for ‘ARKG’By Tom LydonFebruary 12, 2021
Smart Beta ChannelToday’s OverARKing Theme? 5 Active ETFs from Ark InvestBy Ben HernandezFebruary 11, 2021
Disruptive Technology ChannelCancer Screening? There’s an ARK ETF for ThatBy Tom LydonFebruary 9, 2021
Disruptive Technology ChannelUnlock the Long-Term Genomics Runway with ‘ARKG’By Tom LydonFebruary 3, 2021
Disruptive Technology ChannelLong Read Sequencing Is Here. The ARKG ETDF Is ReadyBy Tom LydonJanuary 29, 2021
Disruptive Technology ChannelTargeted ETF Strategies to Capture Technological BreakthroughsBy Max ChenJanuary 27, 2021
Disruptive Technology ChannelAn ‘Omics Revolution: What’s Next for High-Flying ‘ARKG’By Tom LydonJanuary 26, 2021
Disruptive Technology ChannelBig Ideas 2021: Technological Breakthroughs Investors Shouldn’t MissBy Max ChenJanuary 25, 2021
Disruptive Technology ChannelARKG: Access the Latest and Greatest Genomics InnovationBy Tom LydonJanuary 21, 2021
Disruptive Technology ChannelCancer Detection & Investing Selection: The ARKG ETFBy Tom LydonJanuary 8, 2021
FeaturedModerna Helps Biotech ETFs Mitigate Massive Losses as Stocks TumbleBy Ian YoungJanuary 4, 2021
Disruptive Technology ChannelDisruption Lurks in 2021. ARKK and ARKG Are Ready For ItBy Tom LydonDecember 30, 2020
